Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis-Reference-Cited by-同舟云学术

Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis

Published:2023-03 Issue: Volume:177 Page:11-20
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

O'Byrne Kenneth,Popoff Evan^ORCID,Badin Firas,Lee Adam,Yuan Yong,Lozano-Ortega Greta^ORCID,Eccles Laura J.,Varol Nebibe,Waser Nathalie,Penrod John R.,Goring Sarah

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference55 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. SEER*Explorer Application.SEER Relative Survival Rates by Time Since Diagnosis, 2000-2018: Adenocarcinoma of the Lung and Bronchus: By Sex, All Races, All Ages, Distant. Accessed May 26, 2022. https://seer.cancer.gov/statistics-network/explorer/application.html.

3. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies;Michielin;J. Immunother. Cancer,2022

4. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials;Dias;Med. Decis. Making,2013

5. Network meta-analysis of survival data with fractional polynomials;Jansen;BMC Med. Res. Method.,2011

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Active Immunotherapy for the Prevention of Alzheimer’s and Parkinson’s Disease;Vaccines;2024-08-28

2. The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-Analysis;2024-07-03

3. Clinical Association Between Immune-related Adverse Events and Treatment Efficacy in Patients With Non-small-cell Lung Cancer Treated With Nivolumab-Ipilimumab-based Therapy;Anticancer Research;2024-06-26

4. Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration;International Immunopharmacology;2024-05

5. Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer;Future Oncology;2024-04